Pharmacyte Biotech, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pharmacyte Biotech, Inc. (Nasdaq: PMCB) on October 30, 2025. The filing reports on the results of a Special Meeting of stockholders held on the same date via live webcast. The meeting addressed three proposals related to capital structure and equity compensation.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Voting Results
At the Special Meeting, 2,866,944 shares (approximately 37.1% of outstanding voting stock) were represented, establishing a quorum. Stockholders approved all three proposals:
- Proposal 1 (Issuance of Shares): Authorized the issuance of common stock underlying convertible preferred stock and warrants issued under a Securities Purchase Agreement dated August 17, 2025, to comply with Nasdaq Listing Rule 5635(d). This issuance exceeds 20% of the pre-transaction outstanding common stock.
- Votes For: 1,649,395
- Votes Against: 249,100
- Abstentions: 47,316
- Proposal 2 (Equity Plan Amendment): Approved an amendment to the 2022 Equity Incentive Plan to increase the number of shares available for grant by 2,250,000 shares.
- Votes For: 2,348,827
- Votes Against: 399,696
- Abstentions: 118,421
- Proposal 3 (Adjournment): Approved the authority to adjourn the meeting to solicit additional proxies if necessary.
- Votes For: 2,496,898
- Votes Against: 311,836
- Abstentions: 58,210
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors beyond the standard disclosure that the description of the Equity Incentive Plan is qualified by reference to the full text attached as Exhibit 10.1. The approval of Proposal 1 indicates the company has recently engaged in a significant capital raise involving convertible securities.
Key Facts for Investor Verification
- Verify the specific terms of the Securities Purchase Agreement dated August 17, 2025, to understand the dilution impact of the convertible preferred stock and warrants authorized in Proposal 1.
- Review the full text of the amended 2022 Equity Incentive Plan (Exhibit 10.1) to assess the total pool of shares now available for employee and director awards.
- Confirm the current outstanding share count to calculate the precise percentage dilution resulting from the August 2025 transaction.
- Monitor future filings for the actual issuance of shares related to the convertible securities approved in Proposal 1.